FA0 Stock Overview
Develops and commercializes diagnostic products in various respiratory diseases, such as asthma, tuberculosis, cystic fibrosis, lung cancer, chronic airway inflammation, and chronic obstructive pulmonary diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PExA AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.022 |
| 52 Week High | SEK 0.046 |
| 52 Week Low | SEK 0.0092 |
| Beta | 0.82 |
| 11 Month Change | -12.20% |
| 3 Month Change | -22.86% |
| 1 Year Change | -44.62% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -59.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| FA0 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 24.1% | -6.1% | -1.3% |
| 1Y | -44.6% | 2.0% | 7.4% |
Return vs Industry: FA0 underperformed the German Life Sciences industry which returned 2% over the past year.
Return vs Market: FA0 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| FA0 volatility | |
|---|---|
| FA0 Average Weekly Movement | 51.4% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FA0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: FA0's weekly volatility has increased from 28% to 51% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3 | Tomas Gustafsson | pexa.se |
PExA AB (publ) develops and commercializes diagnostic products in various respiratory diseases, such as asthma, tuberculosis, cystic fibrosis, lung cancer, chronic airway inflammation, and chronic obstructive pulmonary diseases. Its research instrument helps lung researchers in the collection of microscopic particles and biomarkers for diseases in the small airways. The company offers PExA 2.0, an instrument for the non-invasive collection of particles in exhaled air.
PExA AB (publ) Fundamentals Summary
| FA0 fundamental statistics | |
|---|---|
| Market cap | €1.49m |
| Earnings (TTM) | -€825.74k |
| Revenue (TTM) | €69.19k |
21.5x
P/S Ratio-1.8x
P/E RatioIs FA0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FA0 income statement (TTM) | |
|---|---|
| Revenue | SEK 795.66k |
| Cost of Revenue | SEK 747.21k |
| Gross Profit | SEK 48.45k |
| Other Expenses | SEK 9.54m |
| Earnings | -SEK 9.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 6.09% |
| Net Profit Margin | -1,193.45% |
| Debt/Equity Ratio | 0% |
How did FA0 perform over the long term?
See historical performance and comparison